http://repository.usmf.md:80/handle/20.500.12710/513 Thu, 14 May 2026 10:47:28 GMT 2026-05-14T10:47:28Z http://repository.usmf.md:80/handle/20.500.12710/1739 Title: Adenoamele hipofizare hormonal-active (secretante) Authors: Vîrtosu, Ana; Alexa, Zinaida; Harea, Dumitru Abstract: The pituitary adenoma are endocrinal benigne tumors with the origin in the epithelial cells of adenohypophysis which evoluate, having functional manifestations, polimorphic endocrines (hypo- or hypersecretions symptoms) and tumoral syndrome of compression of adjacent tisues. We will present cases of two patients with secreted hypophyseal adenoma (somatotrophic tumor in the first case and ACTH-producing pituitary tumour in the second case). The purpose of these presentations consists in the evaluation of clinical consequences and other issues related to diagnosis and treatement of the secreting adenoma of the pituitary gland. Adenoamele hipofizare sunt tumori endocrine benigne cu origine în celulele epiteliale ale adenohipofizei care evoluiază cu manifestări funcţionale, endocrine polimorfe (simptome de hipo- sau hipersecreţie adenohipofizară) şi sindrom tumoral de compresie a ţesuturilor adiacente. Se prezintă cazurile clinice a 2 paciente cu adenoame hipofizare secretante (somatotropinom în primul caz şi corticotropinom în cel de-al doilea). Scopul prezentării constă în evaluarea şi diagnosticarea precoce a consecinţelor clinice şi a problemelor de diagnostic şi tratament a adenoamelor hipofizare hormonal active. Description: Catedra Endocrinologie USMF „Nicolae Testemiţanu” Tue, 01 Jan 2008 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/1739 2008-01-01T00:00:00Z http://repository.usmf.md:80/handle/20.500.12710/1738 Title: Evoluţia maladiei tiroidiene Graves-Basedow şi importanţa anticorpilor anti-tiroidieni Authors: Baltag, Natalia Abstract: In Graves’ disease the dosage of TSH antireceptor antibodies can be a helpful element in treatment management. When TSH antireceptor antibodies’ level is increased, it is not recommended to stop the treatment with anti-thyroidians of synthesis, because of the high risk of relapse. Persistence of a high level of anti-TPO antibodies may possibly subsequently result into hypothyroidism. În cadrul bolii Graves-Basedow, dozarea a anticorpilor anti-receptori TSH poate constitui un element ajutător pentru dirijarea tratamentului: cînd titrul e ridicat, nu e cazul de a sista tratamentul fiind sporit riscul recidivelor. Persistenţa titrului înalt de anticorpi anti-TPO face posibilă instalarea unei ulterioare hipotiroidii. Description: Catedra Boli interne nr1 FR USMF „N. Testemiţeanu”, SCM „Sfînta Treime” Tue, 01 Jan 2008 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/1738 2008-01-01T00:00:00Z http://repository.usmf.md:80/handle/20.500.12710/1737 Title: Unele aspecte ale manifestărilor cardiovasculare la pacienţii cu tireotoxicoză Authors: Harea, Dumitru Abstract: Cardiac manifestations in hyperthyroidism have varied clinical aspects. These include pulmonary hypertension and atrial fibrillation. Pulmonary hypertension has been associated with thyroid disease or presence of antithyroid antibodies. The exact mechanism of the pulmonary hypertension in hyperthyroidism is not known, but could be related to hemodynamic or autoimune processes. Treatment of thyrotoxicosis can improve parameters of pulmonary hypertension. Manifestările cardiovasculare în tireotoxicoză sunt variate, incluzînd hipertensiunea pulmonară (HP) şi fibrilaţia atrială. HP se asociază atît cu boli tiroidiene, cît şi cu markeri ai autoimunităţii tiroidiene. Mecanismele dezvoltării HP în HT nu sunt definitiv elucidate. Sunt presupuse modificări hemodinamice şi proce autoimune. Tratamentul tireotoxicozei ameliorează hemodinamica pulmonară. Description: Catedra Endocrinologie Tue, 01 Jan 2008 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/1737 2008-01-01T00:00:00Z http://repository.usmf.md:80/handle/20.500.12710/1736 Title: Recidivarea tirotoxicozei după tratamentul chirurgical al pacienţilor cu guşă difuză toxică Authors: Caradja, Gheorghe; Anestiadi, Zinaida; Harea, Dumitru Abstract: The study covered 96 patients with diffuse toxyc goiter (DTG) who had received conservative thyrostatic therapy of varying duration. Five years after operation for DTG (subtotal thyroidectomy), recurrent thyrotoxicosis developed in 14,6% of cases. The risk factors of recurrent thyrotoxicosis included young age(under 35 years), a large size of goiter (more than 30 ml), the absence of decrease or an increase in the volume of the thyroid gland during therapy, and conservative thyrostatic therapy for a short time (under 3-6 months). Studiul a cuprins 96 pacienţi cu guşă difuză toxică (GDT), care, la debutul bolii, au primit tratament tirostatic de diferită durat. După 5 ani de la tratamentul chirurgical al GDT (tiroidectomie subtotală), recidivarea tirotoxicozei s-a înregistrat în 14,6 % cazuri. Factorii de risc a recidivării tirotoxicozei includ vârsta tânără (sub 35 ani), volumul mare al guşii (peste 30 ml), absenţa micşorării sau creşterea volumului tiroidei pe fondalul tratamentului conservativ şi tratamentul tirostatic conservativ pe termen scurt (până la 3-6 luni). Description: Catedra Endocrinologie Tue, 01 Jan 2008 00:00:00 GMT http://repository.usmf.md:80/handle/20.500.12710/1736 2008-01-01T00:00:00Z